An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
LA JOLLA, Calif.--(BUSINESS WIRE)--
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 10, 2022, at 7:00 am EST.
The presentation will provide a high-level overview of itolizumab’s mechanism of action followed by topline data from the company’s Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD), regulatory feedback leading directly to a pivotal study in aGVHD, and the EQUALISE study in systemic lupus erythematosus and lupus nephritis. Members of Equillium’s leadership team will be available for one-on-one meetings during the conference.
About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.